Chernett Jorey sold 100 derivative units of Starling Oncology, Inc. at $6.24 for −$624 on Aug 13, 2026

Sell
Form 4 code S. Open-market or private sale of a non-derivative or derivative security.
10% owner
10%
Filed Aug 17, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
−$624Shares × reported price
Shares traded
100Call Option (STLN 19FEB27 $9C)
Price per share
$6.24Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
0Direct
Trade date
Aug 13, 2026Sell
Filed
Aug 17, 2026, 10:13 AM ET4-day reporting delay
Accession
0000921895-26-002203Code S · Transaction 158
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Aug 14, 2026Buy12,000$6.54$78,480Trade 157
2 transaction rows in this filing. Joint filers share the same rows.

STLN price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
STLN · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −13%1w ago −19%1d ago −19%
Returns since7d −2.9%30d +3.5%90d −45%180d1y

Footnotes in full

F1: The sale of these call options is a matchable transaction subject to Section 16(b) of the Securities Exchange Act of 1934. The reporting person has calculated a short-swing profit in connection with such matchable transactions, which the reporting person intends to disgorge to the Issuer.